Financial Comparison: Virios Therapeutics (NASDAQ:VIRI) and Vincerx Pharma (NASDAQ:VINC)

Valuation and Earnings

This table compares Vincerx Pharma and Virios Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16 million	($5.31)	0.00
Virios Therapeutics	N/A	N/A	-$5.30 million	($0.27)	-6.11

Virios Therapeutics is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vincerx Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

Profitability

This table compares Vincerx Pharma and Virios Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Virios Therapeutics	N/A	-130.33%	-115.00%

Institutional & Insider Ownership

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Virios Therapeutics beats Vincerx Pharma on 5 of the 8 factors compared between the two stocks.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

About Virios Therapeutics

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.